FDA Inspection 775234 — Damien Sanderlin, MD
The FDA completed an inspection of Damien Sanderlin, MD on March 29, 2012 in Houston, TX. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 1 citation was issued during this inspection. Product area: Biologics.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- March 29, 2012
- Fiscal Year
- 2012
- Product Type
- Biologics
- Project Area
- Bioresearch Monitoring
- Location
- Houston, TX (United States)
Additional Details
Clinical Investigator (CI)
Citations
| ID | CFR | Description |
|---|---|---|
| 2970 | 21 CFR 812.100 | Investigator lack of informed consent |